Navigation Links
IMPAKT -- Translational research breast cancer conference
Date:4/11/2013

"What is discussed at IMPAKT can directly lead to new ways of designing trials that would hopefully lead to new protocols in the course of the next few years and could change outcome for patients."

Andrew Tutt and Peter Dubsky, IMPAKT 2013 Co-Chairs

IMPAKT 2013 will build on topics discussed in previous years and will focus specifically on the following areas Watch the video here[http://www.youtube.com/watch?v=X_anpC5WZPg]:

  • Breast cancer heterogeneity - Mechanisms, capturing, and clinical implications
    • How much is there at the start and how much happens over time
    • Can host immune response beat tumour heterogeneity or does it complicate outcomes?
    • Dissemination and organ specific metastasis of breast cancer: How does heterogeneity play a role?
    • Can heterogeneity in advanced breast cancer be captured by molecular imaging?
  • Targeting the PI3K/AKT/mTOR axes in breast cancer: targets, trials and biomarkers
  • Cancer reprogramming induced by treatment: Is it a problem and can we predict and inhibit it in the clinic?
  • Biomarker driven neoadjuvant trials in breast cancer
  • How to avoid false positive and false negative results in the assessment of oestrogen and progesterone receptor status
  • In a world of breast cancer heterogeneity is the biopsy of metastasis helpful or distracting?
  • Integrating breast cancer genomics and proteomics - shooting for the moon

The full conference programme is available at http://www.esmo.org/events/breast-2013-impakt/program.html

The 2013 Press Programme will capture the very essence of the IMPAKT conference, where the ultimate goal is to improve breast cancer outcome through translational research, i.e. new techniques, new concepts on the cutting edge to change the clinic as soon as possible:

  • Biomarker data including
    • Predicting risk for late metastasis: the PMA50 risk of recurrence (ROR) score after 5 years of endocrine therapy in postmenopausal women with HR+ early breast cancer: a study on 1,478 patients from the ABCSG-8 trial (53 O)
    • Prognostic and predictive value of IHC4 and ERB1 in the integroup exemestane study (IES) on behalf of the pathies investigators (55 O)
    • Comparison of five different scores for the prediction of late recurrence for oestrogen receptor positive breast cancer (54 O)
    • Predictive value of AKT/mTOR pathway immunohistochemical (IHC) biomarkers for response to pre-operative trastuzumab vs. trastuzumab + everolimus in patients with early breast cancer: UNICANCER RADHER trial results (56 O)
  • Heterogeneity of breast cancer including
    • Contribution of analytical, pre-analytical and intra-tumoral heterogeneity to variance in gene expression measurements from human breast cancers (40 O)
    • Heterogeneity of genomic signatures in breast cancer core biopsy (41 O)
    • Assessment of Genetic Alterations in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer From the BOLERO-2 Trial by Next-Generation Sequencing (42 O)

Press conference

Thursday, 2 May 2013, 10:45-11:45 (CEST)

Hosts: Martine Piccart, Jules Bordet Institute, Head of Chemotherapy Unit, Brussels, Belgium, IMPAKT Co-Founder Peter Dubsky, Vienna General Hospital (AKH) - Medizinische Universitt Wien, Vienna, Austria, IMPAKT2013 Scientific Chair Andrew Tutt, King's College London Guy's Hospital, London, United Kingdom, IMPAKT2013 Executive Chair

BIG and ESMO welcome media interested in obtaining information and reporting on cancer issues. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card. Media representatives are required to observe and abide by the Media Policy < http://www.esmo.org/fileadmin/media/pdf/2013/events/IMPAKT-2013/ESMO-IMPAKT-2013-Media-Policy.pdf >. A press centre with facilities will be available to registered journalists (Lounge on the mezzanine).

Please contact the IMPAKT Press Office at media@esmo.org to request press releases, schedule remote interviews or register for the event. < http://www.formstack.com/forms/esmo-media_application__5th_impakt_breast_cancer_conference__brussels > Media registration in advance is strongly recommended although on-site registration will still be possible.

Embargo Policy

Abstracts accepted for poster presentation and for publication in the IMPAKT Abstract book will be made public online on Monday, 22 April 2013 and will be accessible at http://www.esmo.org/events/breast-2013-impakt/program.html

Abstracts accepted for oral presentation and abstracts selected for the official IMPAKT Press Programme will be embargoed until the official opening of the IMPAKT 2013 Conference, Thursday, 2 May 2013, 12:00 (CEST)

Journalists are required to observe embargoes as indicated, thank you!

Around 500 attendees are expected from throughout Europe and the rest of the world.


'/>"/>

Contact: ESMO PRess Office
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. Fourth IMPAKT Breast Cancer Conference
2. Hot topics in translational bone research at IOF-ESCEO 3rd Pre-Clinical Symposium
3. Autism Speaks and SAGE® Labs develop rat models for translational autism research
4. Elsevier launches new open access journal: Applied and Translational Genomics
5. BUSM researchers identify novel approach to study COPD and treatment efficacy
6. LSUHSC research discovers new drug target for metastatic breast cancer
7. Researchers call for marine observation network
8. Biofilms help Salmonella survive hostile conditions, Virginia Tech researchers say
9. Feinstein Institute collaborates with GSK, UPenn, MIT to research bodys electrical impulses
10. U-M researchers find new way to clear cholesterol from the blood
11. New cutting-edge cell research will lead to safer medical experiments on humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... -- Trovagene, Inc. (NASDAQ: TROV ), a developer ... it has signed agreements with seven strategic partners across ... Middle East for commercialization of the Trovera™ ... of international distribution agreements for Trovagene,s CLIA based liquid ... The initial partners will introduce Trovagene,s liquid biopsy tests ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
(Date:1/3/2017)... Onitor, provider of digital health technology for ... innovative biometric data-driven program designed to aid weight loss ... 2017 Consumer Electronics Show (CES) in Las ... the World Health Organization (WHO), have identified lifestyle risks ... are overweight or obese. WHO also states that more ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... ... January 17, 2017 , ... One Million Solutions ... (SafeTEC™), $3 million in investment towards 15+ TEC Validation Projects™. As a pre-competitive ... their applicability in drug safety assessment, for the industry as a whole. , ...
(Date:1/17/2017)... -- On January 10 at the Medtech Showcase held in ... in San Francisco , ProclaRx CEO, ... pharmaceutical leaders and public and private investors about the ... destroy biofilms.  Biofilms are a physical ... body,s immune system from eradicating chronic infections. Infections with biofilms ...
(Date:1/16/2017)... , Jan. 16, 2017  Eurofins Genomics today ... will allow more customers to receive their primers in ... or compromise in quality found with other providers. Express ... United States at no additional fee. ... routine genetic studies, including DNA sequencing, genotyping, site-directed mutagenesis, ...
(Date:1/13/2017)... Research and Markets has announced the addition of the "Global ... ... CAGR of 16.83% during the period 2017-2021. The report ... market for 2017-2021. To calculate the market size, the report considers the ... also includes a a discussion of the key vendors operating in this ...
Breaking Biology Technology: